Vanda Pharmaceuticals shares are up 75c, or 16%, to $5.59 after the company confirmed that it has received a revised unsolicited proposal from Future Pak to acquire the company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights, or “CVRs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA: